+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Uveitis Drugs Market 2019-2023 - Product Image

Global Uveitis Drugs Market 2019-2023

  • ID: 4774795
  • Report
  • June 2019
  • Region: Global
  • 130 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
Several risk factors associated with uveitis had been a challenge during the diagnosis of eye disorders. Considering the complexities related to the diagnosis, vendors in the market are developing novel diagnostic tools and methods to treat patients with uveitis. Several companies are introducing AI-implemented medical devices to detect the level of diabetic retinopathy in patients with diabetes. Devices integrated with AI work autonomously and eliminate the need for specialists to make clinical decisions. Many such advancements have made the diagnosis of eye conditions easier. Ophthalmologists are leveraging such technical advantages and are providing the right treatment to patients. This is expected to drive the growth of the global uveitis drugs market size at a CAGR of around 7% during 2019-2023.

Market Overview

High prevalence of eye disorders and associated risk factors of uveitis

Uveitis is associated with several inflammatory diseases that cause swelling and destroy eye tissues. People with AIDS, rheumatic arthritis, multiple sclerosis, TB, and syphilis are more vulnerable to eye-related risk factors. The high prevalence of these diseases will have a positive impact on the market’s growth.

Availability of substitutes

Despite the availability of approved drugs, healthcare practitioners are adopting alternative treatment options such as surgery, laser treatment, and biopsy due to the side-effects associated with uveitis drugs. This is expected to hinder the growth of the global uveitis drugs market during the forecast period.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as AbbVie Inc. and Allergan Plc have intensified competition. Factors such as the recent advancements in the diagnosis of eye disorders and the high prevalence of eye disorders and associated risk factors of uveitis will provide significant growth opportunities for uveitis drug companies. AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Development of gene therapy
  • Special designations
  • Increasing popularity of combination therapies
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Allergan Plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global ophthalmology drugs market
Exhibit 02: Segments of global ophthalmology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Some of the generic sponsors for corticosteroids
Exhibit 21: Different forms of corticosteroids
Exhibit 22: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 23: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the biologics used in uveitis
Exhibit 25: Cost of some biologics
Exhibit 26: Some of the approved biosimilars
Exhibit 27: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Prevalence of associated risk factors for uveitis
Exhibit 47: Drug development pipeline late stage molecules for uveitis
Exhibit 48: Adverse effects associated with available drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie Inc. - Vendor overview
Exhibit 56: AbbVie Inc. - Business segments
Exhibit 57: AbbVie Inc. - Organizational developments
Exhibit 58: AbbVie Inc. - Geographic focus
Exhibit 59: AbbVie Inc. - Key offerings
Exhibit 60: AbbVie Inc. - Key customers
Exhibit 61: Allergan Plc - Vendor overview
Exhibit 62: Allergan Plc - Business segments
Exhibit 63: Allergan Plc - Organizational developments
Exhibit 64: Allergan Plc - Geographic focus
Exhibit 65: Allergan Plc - Segment focus
Exhibit 66: Allergan Plc - Key offerings
Exhibit 67: Allergan Plc - Key customers
Exhibit 68: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 69: Johnson & Johnson Services, Inc. - Business segments
Exhibit 70: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 71: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 72: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 73: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 74: Johnson & Johnson Services, Inc. - Key customers
Exhibit 75: Novartis AG - Vendor overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Organizational developments
Exhibit 78: Novartis AG - Geographic focus
Exhibit 79: Novartis AG - Segment focus
Exhibit 80: Novartis AG - Key offerings
Exhibit 81: Novartis AG - Key customers
Exhibit 82: Pfizer Inc. - Vendor overview
Exhibit 83: Pfizer Inc. - Business segments
Exhibit 84: Pfizer Inc. - Organizational developments
Exhibit 85: Pfizer Inc. - Geographic focus
Exhibit 86: Pfizer Inc. - Segment focus
Exhibit 87: Pfizer Inc. - Key offerings
Exhibit 88: Pfizer Inc. - Key customers
Exhibit 89: Validation techniques employed for market sizing
Exhibit 90: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global uveitis drugs market: AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of gene therapy.”

According to the report, one of the major drivers for this market is the recent advancements in the diagnosis of eye disorders.

Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Allergan Plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll